<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">15083692</PMID>
        <DateCompleted>
            <Year>2004</Year>
            <Month>08</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1220-0875</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>59</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2003</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Oftalmologia (Bucharest, Romania : 1990)</Title>
                <ISOAbbreviation>Oftalmologia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Neuroprotection with carotenoids in glaucoma].</ArticleTitle>
            <Pagination>
                <MedlinePgn>70-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of the paper was to assess the place of the natural carotenoids (lutein, zeaxanthin) in glaucoma optic neuropathy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">For this purpose, we carried out an experimental and prospective study, during 3 months, on 8 laboratory animals (Guinea pigs), which we increased the IOP, in both eyes, by cautery of two episcleral vessels. The animals were divided into treatment in two groups: the group I (5 Guinea pigs) which we modified their usual diets by adding 2 cps/day of IcapsL (6 mg lutein/zeaxanthin) and the group II (3 Guinea pigs)--control group, without increasing the diet with lutein and zeaxanthin. The statistical analysis was performed by Student's t test.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Before the cautery of episcleral vessels, the mean IOP was 16.8 mm Hg in group I and 16.5 mm Hg in the group II; after the cautery of episcleral vessels, the mean IOP was 26.2 mm Hg in group I and 25.9 mm Hg in the group II (p = 0.004). At the end of the study, the levels of serum lutein were 0.64 mumol/L in group I and 0.22 mumol/L in group II. The loss of retinal ganglion cells was 18.9% in group I and 29.7% in martor group, in correlation with the cup/disc ratio: 0.37, respectively 0.51. Also, in the group II, the increase of IOP was associated at the myelin portion of optic nerve head with axonal degeneration in peripheral regions.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Glaucoma optic neuropathy has a multifactorial pathogenesis, including the oxidative stress. Lutein and zeaxanthin, with its strong antioxidative effects, can represent a viable solution in the complex treatment of glaucoma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Neacşu</LastName>
                    <ForeName>Alina</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oprean</LastName>
                    <ForeName>Carmen</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curea</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuchilă</LastName>
                    <ForeName>Gabriela</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trifu</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>rum</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Neuroprotecţia prin carotenoizi în glaucom.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>Romania</Country>
            <MedlineTA>Oftalmologia</MedlineTA>
            <NlmUniqueID>9111247</NlmUniqueID>
            <ISSNLinking>1220-0875</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>36-88-4</RegistryNumber>
                <NameOfSubstance UI="D002338">Carotenoids</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002338" MajorTopicYN="N">Carotenoids</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005901" MajorTopicYN="N">Glaucoma</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>8</Month>
                <Day>11</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15083692</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>